Photo from wikipedia
Paritaprevir/ritonavir/ombitasvir+dasabuvir (PrOD) is a direct‐acting antiviral (DAA) approved for the treatment of chronic hepatitis C virus. We report on a probable interaction between PrOD with ribavirin and warfarin. Click to show full abstract
Paritaprevir/ritonavir/ombitasvir+dasabuvir (PrOD) is a direct‐acting antiviral (DAA) approved for the treatment of chronic hepatitis C virus. We report on a probable interaction between PrOD with ribavirin and warfarin.
Keywords:
paritaprevir ritonavir;
report;
ritonavir ombitasvir;
ombitasvir dasabuvir
Journal Title: Journal of Clinical Pharmacy and Therapeutics
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Pharmacy and Therapeutics
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!